Gyre Therapeutics (GYRE) FCF Margin (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly FCF Margin of 13.42% for Q1 2026, up 1456.0% year-over-year from 0.86% in Q1 2025, and up 187.05% quarter-over-quarter from 15.42% in Q4 2025.
Gyre Therapeutics (GYRE) FCF Margin (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported FCF Margin for 16 consecutive years, with 13.42% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 1456.0% year-over-year to 13.42%; the TTM figure through Mar 2026 stood at 2.64% (up 1145.0% YoY), while the FY2025 annual figure was 0.15%, up 548.0% from the prior year.
- FCF Margin grew to 13.42% in Q1 2026 per GYRE's latest filing, from 15.42% in the prior quarter.
- Across five years, FCF Margin topped out at 41.67% in Q4 2022 and bottomed at 1517.63% in Q1 2022.
- Historically, FCF Margin has averaged 94.63% across 5 years, with a median of 7.0% in 2025.
- On a YoY basis, FCF Margin climbed as much as 155243 bps in 2023 and fell as far as 3786 bps in 2023.
- Gyre Therapeutics' FCF Margin stood at 41.67% in 2022, then tumbled by 91 bps to 3.82% in 2023, then sank by 353 bps to 9.66% in 2024, then sank by 60 bps to 15.42% in 2025, then soared by 187 bps to 13.42% in 2026.
- Business Quant data shows GYRE's FCF Margin at 13.42% in Q1 2026, 15.42% in Q4 2025, and 12.86% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -58.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -58.44% |
| Mar 31, 2026 | 13.42% |
| Dec 31, 2025 | -15.42% |
| Sep 30, 2025 | 12.86% |
| Jun 30, 2025 | 7.00% |
| Mar 31, 2025 | -1.14% |
| Dec 31, 2024 | -9.66% |
| Sep 30, 2024 | 4.05% |
| Jun 30, 2024 | -27.55% |
| Mar 31, 2024 | 9.76% |
| Dec 31, 2023 | 3.82% |
| Sep 30, 2023 | 17.50% |
| Jun 30, 2023 | 7.01% |
| Mar 31, 2023 | 34.80% |
| Dec 31, 2022 | 41.67% |
| Mar 31, 2022 | -1,517.63% |
| Dec 31, 2021 | -735.89% |
| Sep 30, 2021 | -960.94% |
| Jun 30, 2021 | -1,777.65% |
| Mar 31, 2021 | -1,660.26% |